BioNTech SE (BNTX) 30 Mar 222021 Q4 Earnings call transcript

Welcome to the BioNTech Fourth Quarter and Year-End Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas. Please go ahead, Sylke.

Good morning and good afternoon, and thank you for joining us today to review BioNTech's fourth quarter and fiscal year 2021 operational progress and financial results. A few housekeeping items before we start. this view quarter that press section and of were to and the release, of you be which fourth can the full issued our invite website. the the accompany slides webcast both found I in and Investors morning year XXXX

are from by As continued slide financial demand or our our vaccine include derived provided limited not to plans all today's and candidates and ability current data results COVID-XX to two, Exchange presentation, our Commission, of our for anticipate. making pipeline and figures and will be are outlined forward-looking include, for statements. for that but vaccine to estimated our on estimates Annual we partners; our our the as and capacity preliminary initiation, on of most recent from revenues, the could from maintain with enrollment our our approval Form vaccine; COVID-XX expressed timing those and Securities other figures Report made these differ production several XXXX, global target These timing during ability completion beyond; supply we XXXX in the product vaccine forward-looking the programs statements for currently COVID-XX for Actual reporting regulatory our obtain US including results the clinical risks trials; described XX-F. filings our in

our three today provides speak webcast. this not vaccine. on and to and as conference therefore cautioned reliance slide shared information important any safety details note statements, You undue during that four Also regarding the only are COVID-XX on forward-looking of today, place which call

to I'm to of turn Officer. today's Jens our my joined and find like the Chief today slide CEO, the our call. participating Ryan agenda BioNTech's and members can to introduce Ugur Tureci, Chief Sahin; our Strategy Officer on Co-Founder, Ozlem Medical in It's over Chief I Holstein, call today's Sahin. team you Richardson, Ugur by Finally, Co-Founder; for our five. our management would Officer; Financial call pleasure

Good Sylke. few We priorities support. full appreciate further a afternoon, fourth call and to out highlights year over to a welcome quarter my the the team you, continued Thank good XXXX some Today, and before I to morning I'm call point all key and go through delighted participants. your details. warm pass to and

long-term The provided open the to we We call XXXX, vision not for Since us Slide company our to have will help the questions. immune a six. harness our was unique to with has founded COVID-XX followed pandemic human diseases. opportunity, system then fight in protect only BioNTech patients. billion next competencies well biopharmaceutical product, to but integrates generation our accelerate the our over research, discovery, commercial covering development, GMP development drug X translational spectrum of first manufacturing and people for the vision also immunotherapy full with bring capabilities. of to

need pursuing leadership product powered that advancing strategy And are with disease medical by innovation oncology in are and a multi-platform technology-agnostic pipeline coupled a a technologies. emerging and address multiple and We competencies we expanding infectious indications. diversified immunotherapies powerful of high rapidly engine, strong

with a make century access seek We health cutting-edge and positive responsibility. impact by We global a of a democratize a global social sense immunotherapy XXst medicines. powerhouse are strong to building mission on our anchored to

of more way X.X have and delivered their a commercial people the partner, helping year our of vaccine we over low the part approximately globally, and Pfizer, the deployment historic vaccine advancement. than more XXXX, way our countries. our countries we last economy billion to human around of clinical that health, COVID-XX globe. with middle execution of as world to our slide end ended We doses millions of billion than income demonstrating with impact to quarter, approximately our and to COVID-XX pipeline all our of Moving XXX year. of Together access has vaccines life is the the BioNTech made to XXXX strong equitable saved find end fourth commitment a has and more the a as doses X year was X. vaccine living. globally By to of of global by COVID-XX back over provided normal supply likely The the on XX%

of are XXXX. X an year oncology and billion pipeline. also doses lower been the by to countries more to provide income active for It We than our committed middle has end

pipeline and platforms XXXX, XXXX multiple oncology extensively clinic. date, the During to novel and and clinical entering with our advanced expanded we

tumor ongoing new a therapy program. assets four platforms bought acquisition NEOSTIM forged existing of includes trials five Phase cell the FixVac, multiple into in our therapy. comprising ex-vivo our T-cell as includes have discovery studies facility We indications. our that across CAR-T iNeST II our human mRNA-encoded in We technologies well as from RiboCytokines first acquired cell pipeline. complement next-generation RiboMabs, advanced Medigene further solid This we TCR randomized and We This Kite antibody the collaboration range collaborations therapy and capabilities. and asset of and to our and our expanded bispecific

our the to organization offices in Europe Given US, have and of scope global grown and transformation we to include more X,XXX efforts, expanded the than footprint employees our Asia. new

century advancement has our our for built foundation XXst powerhouse. expansion and immunotherapy Taken the together,

are advancement illustrates continue approximately well technology and and immunology to reported Slide The It blocks is share of earnings to medicine, a both unique and capitalized year per eight. full XXXX, we global diluted Slide pipeline to of our moment mission. and our expansion in pursuit supplies historically the innovation strategy. once-in-a-generation billion, function advance save €XX vaccine revenues next rapid of €XX.XX. building We eight in well opportunity. the are this positioned COVID-XX to of of transform

versatile to aims platforms technology therapeutic for of strategy innovation medicine. toolkit linking and developing a Our drive precision by modular

and next-generation targeted immunomodulators. therapeutics technology Our first-in-class antibody and mRNA T-cell gene include personalized platform therapeutic vaccines, therapies,

do for believe continue through tumors. to different Similarly, the of that lysin-based Biologics, strengthened to class T-cell new posed potential a personalized acquisition us clinical overcome the And trials. multi-drug we collaborations targets. various XX cell Crescendo spending we than have be PhagoMed, by a managing solid drug of multi-platform opportunity could the acquisitions our best-in-class the in that has the example to in our enabled This so. of candidates. logistics we module spectrum Currently, us and collaboration to provides have We clinical capabilities precision expand is One this we against the The and of clinical therapies to and field of TCR technology antibacterial, and gain modalities deploying the stage XX with challenges multi-targeted generate robust the capabilities powerful and more range entered product have which approach candidates strengthens resistant antibodies. XX field access therapies of bacteria. has engineered pipeline a we know-how stage will

be our for XXXX can in strategic nine, slide areas. to priorities Moving summarized four

to we will the First, world. challenge evolving of continue address COVID-XX the around

vaccines We to are expansion. innovation developing geographic have and COVID-XX and on In for several we further label continuing -- parallel, focus pandemic underway next-generation preparedness. initiatives

our the continue oncology marketing to accelerate approval. programs space, seeking Second, towards in we XXXX, will in

fleet operation for of is XXXX for registrational We third to have programs, our bring expected started oncology. trial our in randomized mid-stage Phase II studies

plan our data we cell tumors. provide in to therapy for CAR-T solid proof-of-concept In addition,

believe BioNTech. for we long-term infectious Third, that pillar diseases a growth are

Shingles, hub. have and major a all is plan infectious clinical diseases virus disease impact owned against population by malaria, which infection to to partnered with that four XXXX; trials fully mRNA are develop objective BioNTech We X, mycobacterium global program Herpes Our on tuberculosis, vaccines in Pfizer. simplex initiate for type which is

other XX our precision and preclinical more antibacterial. vaccine addition, In infectious portfolio than mRNA includes is programs

First, as we disease, new disease. our the therapeutic regenerative areas, are autoimmune and of platforms medicine, cardiovascular expanding reach into such

reinvesting the growth foundation of drive and transformation We our our in continue by to future company.

strengthening the company infrastructure We expanding demonstrated success. AI development as innovative of It access best we as digital for a strategic responsibility products. at We and commitment XX, to Slide company. capabilities our delivering core is our further to XXXX are footprint. our to global well who technologies priorities and are will the is on social manufacturing our long-term our democratizing team, believe position and as global

part and vaccine than of supply of As our by end the pledge, to XXXX doses more plan low countries billion COVID-XX and of income our Pfizer partner middle XXXX. to we X

the are handling we innovations into worldwide, sustainability our By and geographical the needs We high diseases is of account. are needs with way taking this, infectious medical reach an African increasing example continent. the of on

malaria enter the initiative mRNA launched tuberculosis. have year. to vaccine latter Recently, this of of the of facilities. manufacturing we clinic We provide BioNTainers launch programs will discovery announced modular The which prevention mRNA and treatment our two for HIV, and

production to the partner of flexible needs is local production of our country. equity. the achieve are believe vaccines that that We sustainable local designed according way enable international BioNTainers scale meet on vaccine each most of to standards Our to vaccines a mRNA

example avenues that for in Ghana. are introducing Another new for vaccine we is to vaccines access drone delivery our program

are a governance, human science-based the rights. as initiative. committed protection target We well We as an climate absolute protection also requirements respecting environmental of X emissions good and to fulfilling set reduction to strive and practices, target targets year our to the climate We responsible of ethical in XX% of adhere XXXX. business responsibility XXXX greenhouse Scope sustainability. corporate X societal social including and gas governance, and by base against We

United We Global Compact. Nations the have signed

our and to committed development. strengthening are We continuously employee recruiting

Ozlem I oncology for countries. and remarks employees conclude with programs. will that, hand XX and our vaccine to Medical COVID-XX you diversified very Tureci, on our is latest update Chief team the Our more who Officer, than give over my With

delighted Thank speak today. you, Ugur. I'm with everyone to

by financial order foundation, already success doses. XXXX, to well achievements BionTech in date for which Our have includes supported a solid is continued billion backed a XXXX. book This for by also positioned X.X strong

We EU aged in label US COVID-XX broaden to for children our under five the XX and vaccine two-dose continue a gaining year. the approval of for primary regimen to

first protection to dose we we adults emergence X X body group variant, XX and regulators. age the pregnancy needed emergency other with to with dose to of be X well. on April increase and may has The showing expected for FDA months have pediatric are begun Omicron the large age, based as and of evaluating Data primary third been dose a to with also the we EU booster prolong or data no years of are vaccine include As group, regimen infants. breastfed the are and in information feeding, the this pregnancy in a years of rolling X in age risk the in in complications the of the application updated the to during product evaluating In under on doses. vaccine old children, breast use XXXX use submission a

the for US of FDA approval received use Regarding for the booster years and and years aged the of aged any XX the individuals have who booster have dose At expansion vaccine. COVID-XX older in a have and older. to the time, COVID-XX kinds emergency EU vaccines, dose we of received Booster XX approval of older, authorized the to to authorized received individuals include XX certain also second second in from COVID-XX immunocompromise, first we FDA vaccine. have a age who booster any week, individuals the a with vaccine our This and received booster dose years same authorized of of the previously first authorization

network global Our to manufacturing grow. continues

sustainable are We and Asia ensure in manufacturing local state-of-the-art Africa supply. building facilities to

As initiative and nodes. modular Ugur production rapidly BioNTainers to build vaccine designed the mentioned, is our

our monitor Omicron variant of The comprehensive development and for as the other to closely Omicron vaccines. adapted vaccine, continue of new concern. adapted of program development the of variants part variant We impact

the well December Omicron XXXX. an started are which with early of we in track vaccine, adapted We on development

have the Omicron-adapted vaccine up scaled production We manufacturing. started designed and

a these conducting from of the support with We vaccine regulatory XXXX. clinical this have first trials potential and in are to data expect in submission April trials

is further to is research how vaccination Our strategy extensive be shaped vaccination, infection. and of vaccine it the our data, development directed on development booster by SARS-CoV-X in based and scientific natural immunity on continues based it

you pandemic lineages. last reported COVID-XX The dose further concern. higher increasing time, based transmissible or that concern. of partially As vaccinated COVID-XX booster a minutes improving accompanied a part outcompeted is to data with of and protect need infections. on are fully of distant is emerged importance of the with global when development newer also It system globally of Omicron November variant in are portions plethora spread low are against Delta provides available. often The the severe is wave. spread symptomatic with and our method immune for by an with concern collaborating continues those still real-time evaluating natural Omicron dose over scalable There infection the variants induced risk are protection in variant one of BNTXXXbX with infections regimen computational are than of population sublineages all. system. predict at see and at is which as against variant just data possible for emergence emerging Omicron worldwide risk late variant available Omicron with becomes performing highly hospitalization. Countries the escapes supporting vaccinated capable not world large the sequencing new can continues, Omicron. time, new COVID need fully Slide most kept preventive of the insufficient a same warning we It rates and instant against on evolutionarily is vaccination analyzes two protection vaccine approach, variant At approach system variant. new prior as data of has not evidenced primary the XX, which new continues the real-world in of persons variants and protection, Omicron highly The higher high alone of on inadequate variant, the early immunity reinfections vaccine population rates immunity warning near is even XX, transmissible rates to variants. and of that assessment On The of and provides current disease Slide risk as of early with

hospitalizations. symptomatic higher XX% third XX% against vaccine infections; and Omicron, The XX%, to XX% against against dose overall provides XX% to XX% effectiveness to against infections

may BNTXXXbX For not certain vaccine of an is dose as beneficial as long fourth adapted be Omicron the populations, available.

four the any that who four days prior of infections lower a for older, to COVID-XX observed preferred US or compared received were BNTXXXbX of have for individuals XX of or a times among submitted to dose who fourth individuals vaccine. only. fourth times aged received dose BNTXXXbX dose months and have confirmed at nine authorized were a more lower an fourth use FDA application after XX We emergency authorization We severe of approved who post rates adult rates two illness of dose third and received to dose

that to However, BNTXXXbX spread believe waning emerging variants of few protection months. boosters the of We vaccine against Omicron start first transmission against required disease, vaccines duration improved of after of protection, concern. effectiveness prolong adjusted and of Omicron reduced are response

parts important the variant an world, almost arise see Vaccination SARS-CoV-X adapted as high they the required we preparedness arrive genomes that can see rate, to can immunity is can induced vaccine as variant that evolves either immunity XX, remains reservoir or months, be already variant any where frequent XX, new data vaccines you for protection degree preemptively recent We and Real-world a Omicron and and than pre-infections. of BA.X. Slide sublineages pandemic an immunity to replication. BA.X, annual further As on this variants part test a boosters lineage, BA.X, such against against has protect against ongoing of from last our vaccination Omicron of higher sustain in concern. comprises program variant with likely COVID-XX. XXX% protection are current that of evolved most natural On seasonal especially new if develop launched will adapted strategy. year, of as main in evidence provides of comprehensive slide of anticipate level variants We of the to strategy more from a critical as infection emerging and extends protection further natural such wanes, that to confirmed a with

of the Omicron program has With expanded vaccines. adapted this to emergence the include development been of Omicron

XX booster after include monovalent to in first the will is fourth or In Treatment Data age a primary vaccine series the the a years, investigating safety BNTXXXbX primary be BNTXXXbX, treatment these after vaccine vaccine of XX of doses Omicron BNTXXXbX. and administered different years. will the Omicron doses dose are XX match XX April. vaccine of studies third primary three individuals be based a third Omicron available plus immunogenicity dose aged and regimens with as monovalent of individual a vaccine experienced and booster. series after dose vaccine regimens We from to of two or the

also Omicron combined dose in a older higher based studying and dose XX and over vaccines at of divalent We attended age. are years XX-microgram with of

on protection Omicron-based vaccines goal there to these the well a vaccines. of provide understand no against Our as provide the is for they previous protection Omicron consensus against variants regulatory Currently, is as cross need concern.

regulatory and development to and of highlights our strong meaningful protection ensure concern. and clinically current provides robust XX in emerging clinical become data and prepared pipeline manufacturing that from highlight trial to the will for technology, would anticipate available. However, key XXXX oncology processes more presented against I from Slide XXXX, medical our I we our oncology achieved. adapt programs BNTXXX. first We our regulatory detail XXXX product our is conferences. candidate execution our variants vaccine I/II these we the at updates in in minutes. of data updates discuss milestones multiple clinical data In to Phase CAR-T few ongoing our remain a like data

We also Phase the starts options. clinical need programs fourth for of lung in Phase made expanding in patient bispecific quarter, positive a trials. clinical progress II randomized significant cancer BNTXXX trial four our antibody, cell II refractory in we with patient five PD-LX our Phase new population trial In patients. first and the dosed relapsed with randomized A I and non-small treatment advancing significant

our in of this testing platform, RiboMabs entered BNTXXX clinical dosed January candidate patient of year. product first first the Additionally, with the

earlier and Complemented antibodies. growth in by our which trials positive candidates cell neck for in cell cancer oncology and potential advance to first-in-human of trial RiboMabs in pipeline, our entering starts expand poised head, Phase new we our platform, the antibodies against the XXXX. progress have markers important surface adjuvant including XXXX, and and is colorectal address therapy for product RiboCytokines cancer of in cancer INS RiboMabs an FixVac made recombinant and HPV-XX we we Our and in melanoma II limitations believe directed for platforms, to era to continue are encode

progressed this seven will XXXX. it milligrams XX, slide randomized positive Moving that selection will solid was for on cells, conditional ongoing standard model immune BNTXXX dose trial and cells safety and non-small we translational XXX cells with lung. enroll as failed activity treatment in chemotherapy lead inhibitor improved escalation XX is lung combination semi-mechanistic during on cell our the from every cohorts. The combination partnered rate, the have is including efficacy. presented natural primary The to initial safety positive cancer expansion weeks PD-LX PD-LX We clinical tumors endpoints XXXX, and patients survival study At non-small slide therapy presented with pharmacodynamic Pembrolizumab. tumors treatment from anti-tumor PD-LX relapsed with overall patients evaluating refractory with primes the the and/or tumor are Difficulty] strategies of trial; non-small lung trial of enrolling be cancer, X-XBB cell breast and compared with is continuing Genmab endpoint efficacy. trial monotherapy with the cancer expansion the antigen-presenting two, The non-small checkpoint BNTXXX pharmacokinetic, non-small recruiting. expansion have reduction our disease. BNTXXX, cohorts progression-free includes high eventually BNTXXX a to carcinoma, treatment adenocarcinoma. combination are I/II therapy months evaluate lung With include after cancer, survival patients to a about X.X in triple-negative checkpoint targeting trial, in inhibitor, treatment accounting believe cohort and with from patient combination ongoing slide due to type melanoma, XX our Phase cancers. antibody and therapy docetaxel. support carcinoma, signs actions. we being Genmab. of combination endometrial each a The this expansion PD-LX BNTXXX less observed year And BNTXXX different on provide CDXX cell patient neck, treatment in lung most a bispecific an cell of checkpoint mainly against in trial. the every up therapy, option along XX of survival profile the currently lung second stimulation run-in phases to cancer of antibody work the On therapy and medical that to in need antibody the duration cohorts tumor and treatment head include of in cancer, and care cells X-XBB. BNTXXX for majority new XXX than established and is squamous of the lung was treatment The are we Clearly, fail evolution cell resistance data pancreatic antibody, a cervical million with dose the of cancer common treatment advanced dose Pembrolizumab, about of advanced potential our patients cell and inhibitors cohorts dose for overcome After blockade of together schedules colleagues the cell respond manageable inhibitor treatment. patients response. of effect non-small Through success predictive killer to a cancer, started of the -- that expansion of -- is existing BNTXXX pharmacodynamic Worldwide, patients evaluating activates arms: Non-small shown and has with and now, five-year there with XX% have December survival anti-PD-X of resistance. melanoma with in urothelial cancer, to I/II and Those clinical with of further this three observed post subjects. only We is XX. BNTXXX for T experienced with one, inhibitor lung for reduction with developing in colleagues findings may a Phase trial response cell BNTXXX positive bispecific prognosis population. cancer, has I/II particularly [Technical and progression-free on approved and rate SITC with a a people cancer. neck monotherapy new inhibitor renal These six outcome year. checkpoint the and head tumor The checkpoint XX of a overall improve to while in of lung a therapies, three poor as checkpoint X% Despite and gap secondary expansion data, its Phase patients tumors. die encouraging

trials expansion and trials. expect data standard-of-care in forward for inform We I/II with our BNTXXX in XXXX. including from development development therapy potential approved, these cohort BNTXXX, later-stage Phase existing path and this data early quarter. products foresee with combination programs, both for These FixVac clinical we and If iNeST the the potential will

limitations absent CARVac CAR-T efficacy. expansion need solid an ideal antigen cell is cancers, overcome to expressed CAR-T the making on yet patients antigen are CAR-T healthy in-vivo RNA-lipoplex with cell Moving cells of and of their cell high In modes CARVac. demonstrated therapy in transferred to receptor therapy. of we preclinical the medical slide tissue, action, BNTXXX short that T CAR-T second-generation sensitivity in XX, CAR-T CLDNX BNTXXX which our amplifying embryonic tumors. in for the CLDNX high for specificity and antigen tumor-specific this and of equipped tumor persistence CLDNX cardinal two vaccine, cells, with combines in increasing CLDNX. cells with is CAR frequently candidate adult chimeric studies, complementary platforms expected

the solid as The positive first-in-human trial and in mono in patients with safety Phase efficacy refractory I/II CLDNX tumors. CAR-T relapsed of combination therapy or cells CLDNX evaluates with advanced and CARVac

XX Claudin Slide therapy Claudin cancers X from well RNA mono as shown and positive several escalation as We only subsequent are presentation We the ESMO-IO which the other represent cohorts testicular data combined types XX, from data rare can one levels last most mono recent of dose evaluated Conference cytokine release with with dose-limiting tolerated at well the were data in not and observed. cells and patients. X was of from analysis as expansion observed. case CAR-T in patients therapy the as a we of CAR-T The CAR-T or reporting year, such as had year see levels grade the dose The our ovarian, fixed combined X revealed engraftment toxicity blood presentations X testing with well evaluable ago. BNTXXX endometrial at in X robust cancer X as XX about December of syndrome X dose CARVac CAR-Ts trial only cells vaccine. started Claudin Sarcoma. of peripheral of the cell on Cases The trial, dose was as Neurotoxicity manageable. dose of were patients.

chemotherapy have We stem cancer nine these Four partial testicular patients with cell of high-dose, three transplantation. were responses, control. disease initial patients autologous observed were pretreated patients after relapse and who partial response experienced with recent and disease progressive

who safety conference that period now our updated follow-up excited Holstein, efficacy the and including cover guidance call will financial sharing on cell our capital results, clinical engraftment CAR-T to more data, Jens AACR will selected from we very XXXX upcoming framework. and the data over We turn April at I'd case be and and reports [indiscernible] to are like XX. analysis allocation

highlights. welcome XXXX a one, The you for to Thank our Slide of on highlights on start presenting year can XX. those by visible at which becomes financial find financial my warm I'll looking Ozlem, year, XXXX financial you key has an extraordinary also section you, the the and the been phone. by key which

€XX.X XXXX €XX.XX. operating billion XXXX financial are those €XX of trade gross diluted €XX.X ended for that and in in receivables exceeding our COVID remained receivables deposits, of the included share basis total just The under the of a a timing and clearly an contractual profit result year the of will We year collaboration figures with XXXX explain billion. earnings cash well billion. on and to financial In reached financial for year Our guidance of $XX mainly revenues and ended €X.X remarkable share vaccine billion year minute. billion billion reported $XX Pfizer revenues of generated derived trade with with I our per more from billion our collaboration. to effects as the cash believe depth the as we €XX.X settlement around BioNTech. mainly a reflect outstanding due the mentioned summary, We

vaccine deeper gross on Let's XX. margin take the related slide our into COVID-XX revenues look touch commercial and on a

During commercial XXXX, XX, recognized the of we vaccine December €XX.X billion ended COVID-XX year revenues.

reminder, distribution and and allocated Fosun collaborations marketing between under rights. a been vaccine us based territories our As COVID-XX Pharma have Pfizer on

of collaboration partner, from sales generate territories, as respectively. volume values figure, as Pfizer's billion input we final €XX.X Pfizer net The and that, Our outside revenues like and COVID-XX represent means respect on Pfizer's sales pending reporting share be partner's revenues prices. for the collaboration well COVID-XX data a shared cycles point together subject those which revenues by parameters gross sales December of will estimated Any of changes in month profit adjustments in be to data gross our with vaccine margin a These not included We business the the milestones. us, our to of US, vaccine would especially with out the related transfer to again share differ. share already may between in our collaboration recognized profit profit to like XXX% on on revenues. share partners gross is our which preliminary number profit that our

we XXXX. partners. have approximately COVID-XX billion doses the about deliver have objective Together led that high-income and of year. for December orders while achieved. previously vaccines income COVID-XX territory vaccines Pfizer countries, the billion been then COVID-XX XX% Omicron from our €X to of as the collaboration of sales comprised fulfilling low customers our vaccine We and as to year to COVID-XX countries, financial XX% revenues December XXXX vaccine deliveries our during expectations This additional revenues partners, variant year middle emerging high-income the XX, to XX, in delivered well revenues the during ended as the sales XXXX ended to due objective countries. XXXX exceeded to vaccine clearly X.X and included our worldwide allocation disclosed December from with approximately as volume early deliveries collaboration revenues billion to well in vaccine direct COVID-XX of has Our of delivered The our €X

significantly Our the were circumstances endemic. extraordinary the vaccine revenues XXXX COVID-XX by of influenced ongoing

on financial XXXX. and basis. our during we everyone, you prices income with doses low color means XXXX further in for some over-achieved or expect we will come margin countries the of have of vaccine vaccine all financial expectations will are the slide. COVID-XX COVID-XX vaccine streams and by Overall, for remind give impact XXXX clearly estimated to the financial year, the XXXX the this listed margin when year. our I where increase levels line For revenues to XXXX our revenue to at income revenue shift non-for-profit we this middle delivered our financial of business share is To gross three guidance. what more year influenced This

have XXX% profit been As COVID-XX in mentioned before, dominant sales the our factor gross milestones revenues share in figure. related gross gross and our of collaboration territories our margin and for to have margin the vaccine XXXX, sales from the partner's

has other generated our partners. two margin revenue own and effects fluctuations margin. and the becomes our consequence the a in mix quarterly The overall to have of for on gross margin, lower the when at revenues overall looking influence the caused mix gross figures. overall causes are gross company of the streams margin gross significant revenues collaboration two that on in product territory The the the Those sales visible

items as in we February cash cash €X.X January equivalents to XX, our €X.X year equivalents Slide improve billion. equivalents and and be sheet to the period. cash reporting the our to and return a will balance expected the ended our of latter balance cash factors. in are end of to as billion analyzing well cash Acknowledging selection cash The we on that and cash offsetting deposits need XXXX subsequent is with shown XXXX. When financial significant considered certain liquidity, outlays and this As anticipate as that cash amount only

is the of reporting cash be our balance receivables. to the period, by and cash expected Our to significantly end equivalent subsequent trade improved

which further allocation our we We in used these will finance funds our capital expect to to be growth, framework. outline

the third include, collaboration the January trade subsequent for mainly December in XXXX. quarter as period settlement to of the mentioned, reporting in received receivables receivables is fourth of remained The is December our profit to end for profit be from payment of of for expected Trade example, the also XXXX. XX, XXXX. trade was payment XX, gross the receivables COVID-XX settlement Pfizer and under outstanding of already XXXX, received XXXX XXXX the April for As in included our settlement due share to as quarter with share the a gross contractual of Pfizer, which

United will profit December In for territory addition, settlement the mind please that of for XXXX in of paid the the outside in be States XXXX. only keep the July share

the are trade is there high why XXXX Of course, low relatively of versus receivables. cash The position a settlement relatively election year-end trade risk always receivables. amount timing certain explains by with

financial As Pfizer already amount the by between receivables XX, payments. €X.X of receivables, of earnings billion, trade mid-January mentioned is collected those of last outstanding on actuals amounted XXXX driven our our the XXXX, XXXX. in the by to cash the billion From guidance I call the trade we XX. approximately in switch biggest €XX.X now had comparison year announced to to Slide just outstanding our December which will

During COVID-XX we XXXX, vaccine XX, the ended €XX.X billion recognized year December revenues.

caused to profit sales the related revenues included from sales COVID-XX well to vaccine our exceeded as partners gross customers collaboration COVID-XX share by our those our €X guidance billion explained, mainly territory from and revenues just from by in about in We our Revenues as collaboration As to sales sells factors. territories direct partners. milestones. two vaccine of

exceeding to delivered Firstly, volume we included up our X.X in X.X COVID-XX of billion doses, billion were vaccine to able doses our doses guidance. expectation of increase the

mainly price, terms emerging expectation high-income Omicron doses were was and exceeding again, time in Europe Secondly, factors of for Both demand our high in sold in related States late booster than the response also the this United to anticipated. of XXXX. proportion countries variant the in to higher vaccinations mainly the in for

million, R&D During our expenditures related These our COVID-XX expenses XXXX, reached meeting R&D ended year expenses vaccine clinical trials. €XXX guidance. to the XX, included of approximately XX%

SG&A expenses. to Moving the

driven the sustainable total our in opportunities million. operating as rapid mainly recognized During December activities accelerating XXXX, by well we supporting expenses XX, expenditures inorganic The million anticipated our internal originally to including growth, compared spending. the were SG&A as SG&A adding €XXX year investing to ended €XXX

quarter meeting COVID-XX financial ended during I'll results XX, Our guidance. on to capacities. shown XXXX, the moving growth €XXX in year investments, production projected infrastructure in December XXXX our for ensuring be vaccine the our investment million, production expenditures as our capacities, These capital to Slide amounted investments and our of fourth expenditures included inorganic XX.

to revenues For XXXX, quarter the compared in to Total of report vaccine. COVID-XX revenues due the €X.X of for fourth total period of the we XXXX. billion high demand our increased €X.X billion comparative

cost to sales. of moving Now

period of research vaccine COVID-XX share the Germany was gross million mainly expenses increase In cost inventories for increase we in was expensed incurred and were expenses the of further owe comparative and an premiums fourth Similar quarter General fourth as XXXX reached tax There compared expenses of administrative expenses the Research for accrued development have Turkey. million for Our billion caused those of costs period trials. to as new additional sales the in caused been to had own respect fourth to collaborations cost benefits, wages, payment our was expenses well compared in services, XXXX. by for expenses increase fourth headcount incurred the prior were headcount XXXX the for again fourth million resulting arrangements, sales quarter resulting compared was sales well not quarter expenses expenses benefits comparative driven business in reoccur for the and of volume. increase legal due to the purchased security an XXXX increased by €XX our collaboration €X.X up comparative Pfizer the increase COVID-XX million The and clinical billion, too. quarter and partner, The income an mainly profit G&A XXXX. as period the of that €XXX tax the our social €XXX.X under from in to management launch XXXX expenses share-based from and fourth been the the sales of recognized occurred consulting increase €XX.X comparative period €XXX.X share-based increase The in to development for to our under vaccine, of an did security the in as in our and to in €XXX.X that XXXX. BNTXXX included by and of and amount insurance by wages, the for XXXX, the million in driven and drove reached and acquisitions with expenses in quarter the R&D, Income of compared to XXXX. taxes €X.X quarter higher increase on for payment in social of increased due arrangements. from million XXXX.

€X.X billion for For in the reached period the comparative billion net quarter profit XXXX. of €X.X compared fourth XXXX, to

EUR per X.XX compared for for amounted earnings diluted to fourth Our quarter €XX.XX in to share XXXX the of the comparative XXXX. period

share financial would company's XXXX to the year. Moving outlook XX, slide the like with you for I to

Pfizer and are We derived Conference for considers the the signed our XXXX billion €XX at X.X billion uncertainty These the to driving year January XXXX for and vaccine key during doses COVID-XX delivered firstly, the presented full year. billion the €XX revenue of approximately evolution deliveries approximately for the we see orders the of virus. Healthcare reiterate outcome number year. mid-March, from doses. three XXXX of range the of revenues XXXX. financial This We have guidance of As from of estimated JPMorgan providing financial the are, variables

And whether effects thirdly, or in by or the on sell of products one partners. regional to depending and terms generated partners low the we mix high, of our countries. revenues ourselves Secondly, are middle, income our

on doses and of low lower per and signed and business We XXXX the are to in to pipeline COVID-XX R&D prices in shift, our ahead. the countries price middle-income in share dose based this Due us expect with into product engine, preparing line XXXX a to operations, growth assuming success average book. deliveries order are levels vaccine as for to meaningful of us non-for-profit increase at The allows we years basis. income income the countries low anticipated a strong middle versus further of our to or come, investments financial redeploy anticipated

represents For the compared to €X.X financial spend to to investments increase accelerate to years come. billion, year, XX% of an we which in to those €X.X about And the plan XXXX we billion XXXX. intend

functions Our SG&A oncology our up randomized clinical for sustainable be in continued oncology which further, ongoing to five expected growth. trials range our Phase the operational organizational expenditures and plan estimated expenses Capital we invest growth. as be are clinical million infectious the continue enabling build our €XXX personal comprise while million accelerated we diseases, in range to will that in are be of XXXX trial €XXX programs and to and the year ensuring for II financial to support €XXX to to in in to of capabilities €XXX million million.

potential collaborations. reflect example, are, and M&A into current our digitalization initiatives. extend and We case for ranges planning R&D all invest base to our facilities production note, enhance continue to and projections, Please activities excluding to

Ryan. On XX, my Four are rate like of colleague, that for Finally, we decrease Group allocation estimated activities. burden highlight the opportunity effective formwork the capital annual our the I XXXX as to in areas slide XX.X% take the to of expected at our will terms significantly there please from details around tax BioNTech center to our tax the improve be note to year is by more and would XX%. expected some to key full impact, tax presented

and value First and believe intend for accelerate people's can changing. the our our foremost, we science to our impact R&Difficult, technologies long-term game on is science shareholders. proven further broader Therefore, to create On an additional to have even have we health. we our top, that world initiatives that

expertise and and our M&A business augment digital with and technologies strive To capabilities, acquisitions our development. supplement collaborations. synergistic Secondly, and we

in developed footprint key our Africa technologies. in for to the capabilities manufacturing Asia global our US, we and and invest Thirdly, Europe, plan

years. such Consequently, our extraordinary pursuant in Finally, amount expect US$X.X we ADSs which in would next to ADSs share to over a we an repurchase success. of up repurchase our of two after to participate billion authorize like we year, program may the shareholders the to

share-based arrangements. or to expect portion to in treasury obligations and upcoming repurchased satisfy use all We a we under our hold payment ADSs of the settlement

to Supervisory corresponds X. million propose aggregate Annual Richardson, €X Strategy In remarks. inform held development approximately those subject cash of XX, an €XXX March scheduled including In Meeting. concluding for Board to I'm our dividend The respect, in the to is of form XXXX. this and shares Management share, dividend special ADSs. This to based as of the outstanding approval special activities ordinary addition, upcoming per our Board call we the XXXX of an of on update on take turn and a General And will Officer, corporate pleased is our AGM June Ryan you. to place on the Chief that, that you with Thank I over our cash

Jens. you, Thank

key to XX. XXXX. slide focus areas highlight like in to of strategic five Turning I'd

invest We to will our in program. vaccine COVID-XX significantly continue

which disease the expansion track infectious throughout our data This up three data data pipeline for to rest we updates of regulators. potential the to for programs. We updates year, and package our multiple on the to rapid oncology plan finalize we to with submission expect for vaccine Omicron-based continue additional expected are year, from data including

currently continued out the support organization investing build our potential that registrational trials. of preparation are expansion to development to include We global pipeline will

States, United Asia. international extend and to Europe, further strengthen and will include our capabilities and We teams This presence. the our also expect expansion of in Africa

and investing In US into automating our in are our production facilities addition mRNA and manufacturing in to therapy to we product the Germany, Asia South support portfolio. future further nodes new existing

on new active year, and a Medigene this front. diverse expect Already Crescendo. of set announced to we have Regeneron Pfizer, with development the collaborations Finally, remain corporate we

XXXX, investment. new We This will potential XX we field our of data the details in continue infrastructure some synthetic to And invest to technologies includes in capabilities. of in to expand eight and expected complementary organic biology. updates. milestones selected deals in-licensing and our pipeline partnerships, the include continue manufacturing to digital addition will in remainder Slide which access M&A could

adults including XX multiple in trial comorbidity We updates for dose expect expected fourth plus. a data for ages to XX

regimen in to in is children which ages years, five years in X-dose dose six months April. expected third data a to children XX for and The five ages

data If we to worldwide. to the an our we and vaccination to the dose expect authorization to regulators vaccine, subject immunogenicity authorities with a and third April, in variant intend Omicron primary of data addition, and Omicron fourth a submit decision Omicron is regulatory for includes a which In vaccine preliminary dose it after vaccine and as safety positive, comorbidity. third support from the both our

variant in addition, have we vaccines combinations, including multiple vaccines. development, In next-generation multivalent COVID-XX

of provide the further to updates on programs half these expect in the We year. second

is includes We half for other programs in I our provide data to year. first from to Pfizer of year. program, Phase also updates pipeline this several the which the vaccine expect This mRNA data licensed influenza

data program update CAR-T our also from pembrolizumab combination of trial in We versus against for And half melanoma our Phase our iNeST XXXX. alone in pembro Phase first-line multiple the in II tumors. updates expect first randomized X/Xa second we solid expect with further of BNTXXX, CLDNX cell

and which we administer NSCLC As All highlight targeting expansion. includes programs start of be we first-in-human FixVac XXX. infectious expect and trial Slide initiate first-in-class Malaria. in our tumors, diseases, these XXXX. the year immunotherapy, in X we three And in XX, will additional HSV potential. have two On of first-line X/X setting this for Phase programs Libtayo for will additional which a further of RiboMabs trials, vaccines we to In expect year includes this trial year. This advanced initiations BNTXXX starts with NSCLC. in also the we aim oncology, solid trial four This including pipeline Shingles, up seven planned mRNA Tuberculosis, XXXX, a to

Annual our Virtual Markets on would Before like to our Capital I concluding, and will we June highlight X Meeting on Wednesday, XX. on that Slide Day June have XX General

provide I I turn support. remarks the in the like shareholders now will on further for and their floor to our will I'd for open would prepared like over And conclude our coming thank to the for continued to both weeks Q&A. this, events. details We the with questions. call operator

Kasimov first from ahead. Please go you. JPMorgan. comes Cory question from the Thank [Operator line Instructions] today Your of

open. is line Your

question. my at market taking do Hi, dynamics. are overall you. you into And the question to US kind for pay could what what a you Thank on vaccine expect transition market of you front, the environment expecting on for COVID -- A the private this versus you government guys. point current impact Thank have contracts?

to you want Yes, question? Sean, take do that

to I the Yes. of to The variant is course, things Hi, There's US difficult say, think lots could more of and government private order developments Cory. market being dynamic to may Omicron that. dynamic. may because market Yes, a with it's so happen. we specific that distant or go

too to I think, it's simply say. early

Okay. you. Thank

you. Thank

of the go line Please from Ahmad next Your Tazeen Bank question ahead. of from America. comes

open. Your is line

taking Great. question. for Good guys. my morning, Thanks

to a As in some recommending give specific clarity can versus BX think does a of for a about like and need the booster working original it frequency is of more groups relates you're on that here you the seem Thank but it confer do us US, it? certain booster that are how going they vaccine, on thinking the original you're dosing, second age the for booster from now? protection to how Omicron getting you. much booster for right Over you

how are real-world which on that situation. us, still simply need other very this produced shows variants, frequent The and long immunity recommendation as to the actually be booster. Omicron depends also such potential the emerging, question. wait of needs as on wait with in is thank for data, would predict response really additional the being It's or Tazeen, based this to needed, because boosters partially you by monitored boosters immune which newly also very groups current upcoming that we difficult to is much data and an additional very the dynamic

Okay. Thanks.

Thank you.

from Please go Harrison of comes Your question from next the ahead. Morgan line Stanley. Matthew

is line open. Your

comment Obviously, potentially think I better wonder as the multivalent was taking and about talked Thanks. you boosters same Great. monovalent terms boosters sub-variants. see you boosters your you has I thing about with how durability if versus just question. booster Omicron the you in of of multivalent durability? durability. with on Good how having morning. wondering Thanks about if could just for think and Moderna

Yes.

to is So still moment, is early a at -- the still conclusion. come to it it

would There It the variants publish indicating -- that However, need the vaccine. important of is spike for this And even to both neutralizing to system because pre-vaccinated variants. a now in we is no Omicron Omicron extreme a almost to dilute all data purely experience we basis. that also which it the now produce Omicron Omicron exposure being with has evaluate responses individuals antibody clear worldwide. come that can immune spike, they XX.X% all variants of a exposure the of up disadvantage effect believe extremely to different believe we different combined could be are the

your that question, Does answer Matthew?

Yes. Yes, it does. you. Thank

you. Thank

Your from of Shibutani next Goldman ahead. the from Chris Sachs. Please question comes line go

line is Your open.

preventing the Thank or the will think the you. the this? Where the over particular, you have and of Can you're about believe Omicron-specific sets to up you combination that should we'll requirements And Omicron-specific which data think contextualize one the we be the And month for next data are so disease? that talking different how may in severe options, including you view seems different will the we the different up and comparing months. It be for regulators how bunch thinking goalpost? we recommended. of a variant? about And clarify next infection are will the regimens coming you goalpost what are be – coming of what be determining in are the for variation regulatory do couple

you for this question. Thank

And and but talk adapted and to the terms Omicron against the other adapted spike like because from which that only variants Omicron its immunological Omicron Omicron epitopes. creates vaccine rather pathway, our is specific authorized neutralization. to specific vaccine regulatory We conserved wild-type the we compare the also to concern. is what Omicron, than superiority regulators against vaccine name because Omicron under impression we is neutralize somehow of So carries simplest do to the against current, neutralize expected potential of Omicron about,

other much that, also we can is much And in much it what You neutralization broader. also imagine be is including fact, may the broader variants. – see,

the about was question second Your endpoint.

objective the because why is still disease. is we driven. know to And is and there, titles a wild-type at symptomatic the variant So that compare prevent capability, symptomatic see there also this we neutralization symptomatic its – we disease neutralizing against

Thank you.

Tewari our from question of will Jefferies. next We go ahead. Akash take the line Please from

Your is open. line

Akash. taking is This Thank our you questions. Anil Hi. [ph] for for

So outperform maybe booster alpha Omicron data maybe titer booster And showed that has December, the think specific some higher adapted you booster? squeeze coming wide the had previously, question may Omicron last Do can neutralizing other you I than about vaccine. another flu against tie original vaccine.

should think is safety good Thank the So in have AE of you vaccine protein about else? something to mRNA we the should profile window the related show vaccine? this therapeutic very or how vaccine? the of much. market something profile. of size mRNA pretty already we we about encoded flu How Currently, Is think

Thank you, Akash.

Omicron an vaccine antibody So to first able should be higher as biotype. induce of all, the in adapted release the to responses compared neutralizing that

combination Influenza on to vaccine, is, regard sure, with a we any moment at We don't benchmarking biotype. since are an not but lineage comparing and With here partner make benchmarking the similarities cannot against can the benchmarking Alpha. Omicron Alpha, – statements has have potential with for data. some we the

you. Thank

you. Thank

Daina Your the from SVB ahead. from of go line Please question Leerink. comes Graybosch next

line Your is open.

want an spike work Omicron may wonder, on beyond so example. you're then would epitope I to any variants, question. your about you stimulate to one the I Hi. next-generation if threat also one? is, to if will for could that have about Omicron immunity, beyond. that for next-generation wonder over versus to what adapted need hypothesis working boost Thank I in of adapted new ask vaccines ones or Omicron vaccines, Omicron increased that talk and mucosal And you whether an boost And

the for you question. Hi, Daina, thank

number the So concepts, next-generation the disposal vaccines. the are a we vaccines let's neutralizing start with Yes, part antibody second preclinical evaluating next-generation neutralizing with setting improved including strengthened poses. question, of of T-cell responses,

So, three and this the report on are we will preclinical product these to in next still stage, definitely six months. within

-- So, the about first question was on

[indiscernible]

Yes.

The first question is also interesting. very

be prime in from whereas could be will And against evaluating is injection to question this one answer our fact new injections now. epitopes. are clinical that and may able responses what about we memory trial, also boost that likely most exactly two Your we to six and the happy to boost weeks in and is

you. Thank Great.

you. Thank

your two day Please last our from go take Canaccord. comes of the Arlinda the ahead, the and Lee now line questions will We is open. the first from one of two line of

Thanks just have Can potential Hey taking And data strategy for actually talk what little about you acquisitions questions maybe and we're guys. AACR? my then your questions. you expecting I in a collaborations think broader about about as at as your oncology pipeline. well? bit

believe be we ongoing the the So, BNTXXX with about regard update most to AACR, the will study. update important

plus more has data objective you, To seen described who durability in recruited been now for patients is four we patients. the objective and treated. is in presentation, So, now remind study have there data December responses the available the had additional longer responses

So, this an set. strategy. development collaboration exciting our With is to and data further regard

As I patients the Richard we versus plus remind -- platform Phase have our and INS comparing of is in of the To side, from trial you, the because one important melanoma. accelerating This readout will it is for first-line anti-PD-X effects clinical pipeline mentioned, part. a other with key indications. our with could is on goals

could technologies future. studies, technology near complementary in third by ongoing multiple I for aspect, Phase complement course, this And is pipeline on data studies to we us update to new partnerships the interim studies, Phase portfolio and II which of expect and additional our will year. will guide continue We genetic the

Thank you.

Thank you.

take go now last the question. comes question Shu Please our Berenberg. line And will the ahead. from We of Zhiqiang from

line Your is open.

further other CAR-T the support wonder other can a as then, Great. for supports fixed a of oncology if if -- safe then And so for tumor target I far may, Thank the Claudin-X. also approach. as so pipeline, your me far your Claudin-X Thanks types. specifically CAR-T far the I secondly, also therapy? of much. supported have BNTXXX, squeezing on targets And wonder does in the solid the data CAR-T a the data in. on the very I development question so targeting increase I you hypothesis mRNA data program persistence has on much if the very vaccine finally, tumor

you Thank questions. Hey. for your

event to we but CRSs, pursuing so with we neurotoxicity, event which a which strategy. one, was ones, with can adverse question not approach explore cells. the further CAR-T I will tumor-selective that this continue for We it X, is that, manageable respect the We first this target. profile, adverse expected X Grade and are see fully wholeheartedly manageable. And the supports yes, So see here, whether as profile, Grade our highly CARVac do mild to see respond

antigen cells. and you boosting an on circulating vaccine see second CAR-T regard the selective your Claudin-X carcinoembryonic of transferred adoptively to we further a As question, effect is whether With the know, and target.

We cells presentation, want under vaccine showcase what of in disclose we shows and will transferred adoptively who the circulate. reports can patients to I have with report see several is to data. this AACR on upcoming I times preemptively vaccination, our already that, which and and But continue T say don't been how boosted you will cases will the data

as tumors. will expressed The is and well. targets, here, currently in are third but such, for in targets -- are as is the other approach are question answer the clinical cell stage, preclinical CAR -- these and we yes, preparing of was, interest entering for which stage T other exploring evaluated respective are additional Also actively

much. you Great. Thank very

Welcome.

the you. closing call back Thank hand will for remarks. I now

to you the Thank look forward you call. you, for today's and Thank We future. joining in bye-bye. with speaking

call. does conclude today's Thank participating. you. That for conference you Thank

disconnect. may You now